secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001437749-24-011212
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track
--------------------------------------------------------------------------------

- Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.
- Private placement of $50M upfront (up to $149.4M with warrants) led by RA Capital; expected to fund through end of 2025.
- RewinD-LB Phase 2b enrollment on track to complete Q2 2024; topline data expected Q4 2024.
- Appointed Joshua Boger, founder of Vertex Pharmaceuticals, as non-executive Chair of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/crvo20240405_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer